Xenograft
PreclinicalSmall molecule
Xenograft is one of 3 small molecule programs targeting Maxillary Sinus Floor Augmentation. It is currently in Preclinical.
3
Indications
7
Total Trials
6
Active Trials
2
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
4 competitors in Bone Graft
#DrugCompanyPhaseTrials
1Xenograft
NNational University of Malaysia
Preclinical
Bioactive Glass
KKing Abdulaziz University
Preclinical
Bio-Oss
Daewoong Pharmaceutical Co. LTD.Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Xenograft2 trials
Post Extraction Changes Following Ridge Preservation Using Partially Demineralized Dentin Block Versus Xenograft
Recruiting·—·N/A·NCT06429540·22 enrolled
Post Extraction Alterations Following Ridge Preservation In The Esthetic Zone Using Partially Demineralized Autogenous Dentine Graft Versus Xenograft
Recruiting·—·N/A·NCT06552793·23 enrolled
Socket Preservation1 trial
Clinical Comparison of Xenograft With Hydrogel Versus Xenograft Alone in the Socket Preservation After Tooth Extraction: A Randomized Controlled Clinical Trial
Not yet recruiting·—·Phase 3·NCT06957197·26 enrolled
Third Molar1 trial
Implant Placement1 trial
Efficacy of Xenograft Alone or Mixed With Arginyl-Glycyl-Aspartic Acid (RGD) in Horizontal Ridge Augmentation With Split-crest Technique for Implant Placement
Recruiting·—·N/A·NCT06585852·18 enrolled
1 more indication
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Xenograft. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- NNational University of Malaysia